Integrated DNA Technologies announces innovation roadmap advances to infectious disease portfolio
Integrated DNA Technologies (IDT) is expanding its infectious disease portfolio with new solutions to enhance worldwide research efforts in monitoring infectious disease dynamics, supporting surveillance and accelerating biomarker discovery.
As part of its innovation roadmap, focused on enabling academic and medical researchers, health organizations, and the scientific community prepare for ongoing and future global health challenges, IDT has unveiled two new tools: The PrimeTime Influenza Kit and PrimeTime Research Pathogen Panels.
Launching at ASM Microbe 2025 is IDT’s PrimeTime Influenza Kit, the first complete qPCR solution of its kind designed specifically to amplify common influenza strains. The kit targets Influenza A, Influenza A (H5N1), Influenza B, and RNase. It includes an internal control for sample quality assessment, a pre-mixed primer and probe set, PrimeTime 4x Broad-Range Master Mix and direct amplification enhancer. This streamlined solution enables researchers to generate high-confidence data for both seasonal and emerging influenza strains.
IDT is also showcasing its new PrimeTime Research Pathogen Panels, a customizable, high-throughput solution that allows researchers to identify key sequences and mutations across 10 diverse research applications—spanning respiratory, gastrointestinal and sexual health studies—and an 11th category for viral infection research. The mix-and-match format across targets and dyes enables scientists to select from a broad list of targets to maximize cost and time savings. The panels’ flexible assay configuration facilitates rapid, multiplexed detection and characterization of pathogens, with up to 211 available targets including sexually transmitted infections, human papillomavirus, urinary tract infections and more.
